High rate of loss to clinical follow up among African HIV-infected patients attending a London clinic: a retrospective analysis of a clinical cohort
Tóm tắt
Long-term regular clinic follow up is an important component of HIV care. We determined the frequency and characteristics of HIV-infected patients lost to follow up from a London HIV clinic, and factors associated with loss to all HIV follow up in the UK. We identified 1859 HIV-infected adults who had registered and attended a London clinic on one or more occasions between January 1997 and December 2005. Loss to follow up was defined as clinic non-attendance for one or more years. Through anonymized linkage with the Survey of Prevalent HIV Infections Diagnosed and Health Protection Scotland, national databases of all HIV patients in care in the UK up to December 2006, loss-to-follow-up patients were categorized as Transfers (subsequently received care at another UK HIV clinic) or UKLFU (no record of subsequent attendance at any HIV clinic in the UK). Logistic regression analysis was used to identify factors associated with UKLFU for those both on highly active antiretroviral therapy (HAART) and not on HAART. In total, 722 (38.8%) of 1859 patients were defined as lost to follow up. Of these, 347 (48.1%) were Transfers and 375 (51.9%), or 20.2% of all patients, were UKLFU. Overall, 11.9% of all patients receiving HAART, and 32.2% not receiving HAART were UKLFU. Among those on HAART, risk factors for UKLFU were: African heterosexual female (OR = 2.22, 95% CI: 1.11-4.56) versus white men who have sex with men; earlier year of HIV clinic registration (1997-1999 OR: 3.51, 95% CI: 1.97-6.26; 2000-02 OR: 2.49, 95% CI: 1.43-4.32 vs. 2003-2005); CD4 count of < 200 versus > 350 cells/mm3 (OR = 1.99, 95% CI:1.05-3.74); and a detectable viral load of > 400 copies/ml (OR = 5.03, 95% CI: 2.95-8.57 vs. ≤ 400 copies/ml) at last clinic visit. Among those not receiving HAART, factors were: African heterosexual male (OR = 3.91, 95% CI: 1.77-8.64) versus white men who have sex with men; earlier HIV clinic registration (2000-2002 OR: 2.91, 95% CI: 1.77-4.78; 1997-1999: OR: 5.26, 95% CI: 2.71-10.19); and a CD4 count of < 200 cells/mm3 (OR: 3.24, 95% CI: 1.49-7.04). One in five HIV-infected patients (one in three not on HAART and one in nine on HAART) from a London clinic were lost to all clinical follow up in the UK. Black African ethnicity, earlier year of clinic registration and advanced immunological suppression were the most important predictors of UKLFU. There is a need for all HIV clinics to establish systems for monitoring and tracing loss-to-follow-up patients, and to implement strategies for improving retention in care.
Tài liệu tham khảo
Antiretroviral Therapy Cohort Collaboration: Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet 2008, 372:293–299.
Smit C, Geskus R, Walker S, Sabin C, Coutinho R, Porter K, Prins M, Collaboration C: Effective therapy has altered the spectrum of cause-specific mortality following HIV seroconversion. AIDS 2006, 20:741–749.
Kaplan JE, Hanson D, Dworkin MS, Frederick T, Bertolli J, Lindegren ML, Holmberg S, Jones JL: Epidemiology of human immunodeficiency virus-associated opportunistic infections in the United States in the era of highly active antiretroviral therapy. Clinical Infectious Diseases 2000,30(Suppl 1):S5-S14.
Grinspoon S, Carr A: Cardiovascular risk and body-fat abnormalities in HIV-infected adults. New England Journal of Medicine 2005, 352:48–62.
Hetherington S, McGuirk S, Powell G, Cutrell A, Naderer O, Spreen B, Lafon S, Pearce G, Steel H: Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir. Clinical Therapeutics 2001, 23:1603–1614.
Nunez M: Hepatotoxicity of antiretrovirals: incidence, mechanisms and management. Journal of Hepatology 2006, 44:S132-S139.
Paterson DL, Swindells S, Mohr J, Brester M, Vergis EN, Squier C, Wagener MM, Singh N: Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Annals of Internal Medicine 2000, 133:21–30.
Low-Beer S, Yip B, O'Shaughnessy MV, Hogg RS, Montaner JS: Adherence to triple therapy and viral load response. Journal of Acquired Immune Deficiency Syndromes: JAIDS 2000, 23:360–361.
Taiwo B: Understanding transmitted HIV resistance through the experience in the USA. International Journal of Infectious Diseases 2009, 13:552–559.
Palella FJ, Baker RK, Moorman AC, Chmiel JS, Wood KC, Brooks JT, Holmberg SD, Investigators HIVOS: Mortality in the Highly Active Antiretroviral Therapy Era: Changing Causes of Death and Disease in the HIV Outpatient Study. JAIDS Journal of Acquired Immune Deficiency Syndromes September 2006, 43:27–34.
Jutte A, Schwenk A, Franzen C, Romer K, Diet F, Diehl V, Fatkenheuer G, Salzberger B: Increasing morbidity from myocardial infarction during HIV protease inhibitor treatment? AIDS 1999, 13:1796–1797.
D. A. D. Study Group, Sabin CA, Worm SW, Weber R, Reiss P, El-Sadr W, Dabis F, De Wit S, Law M, D'Arminio Monforte A, Friis-Møller N, Kirk O, Pradier C, Weller I, Phillips AN, Lundgren JD: Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet 2008, 371:1417–1426.
British HIV Association: Standards for HIV Clinical Care. 2007.
Perez-Hoyos S, Rodriguez-Arenas MA, Garcia de la Hera M, Iribarren JA, Moreno S, Viciana P, Pena A, Gomez Sirvent JL, Saumoy M, Lacruz J, Padilla S, Oteo JA, Asencio R, del Amo J: Progression to AIDS and death and response to HAART in men and women from a multicenter hospital-based cohort. Journal of Women's Health 2007, 16:1052–1061.
Kitahata MM, Gange SJ, Abraham AG, Merriman B, Saag MS, Justice AC, Hogg RS, Deeks SG, Eron JJ, Brooks JT, Rourke SB, Gill MJ, Bosch RJ, Martin JN, Klein MB, Jacobsen LP, Rodriguez B, Sterling TR, Kirk GD, Napravnik S, Rachlis AR, Clazavara LM, Hoberg MA, Silverberg MJ, Gebo KA, Goedert JJ, Benson CA, Collier AC, Van Rompaey SE, Crane HM, McKaig RG, Lau B, Freemand AM, Moore RD, NA-ACCORD Investigators: Effect of early versus deferred antiretroviral therapy for HIV on survival. New England Journal of Medicine 2009, 360:1815–1826.
Yu JK, Chen SC, Wang KY, Chang CS, Makombe SD, Schouten EJ, Harries AD: True outcomes for patients on antiretroviral therapy who are "lost to follow-up" in Malawi. Bulletin of the World Health Organization 2007, 85:550–554.
Karcher H, Omondi A, Odera J, Kunz A, Harms G: Risk factors for treatment denial and loss to follow-up in an antiretroviral treatment cohort in Kenya. Tropical Medicine & International Health 2007, 12:687–694.
Dalal RP, Macphail C, Mqhayi M, Wing J, Feldman C, Chersich MF, Venter WD: Characteristics and outcomes of adult patients lost to follow-up at an antiretroviral treatment clinic in johannesburg, South Africa. Journal of Acquired Immune Deficiency Syndromes: JAIDS 2008, 47:101–107.
Ioannidis JP, Taha TE, Kumwenda N, Broadhead R, Mtimavalye L, Miotti P, Yellin F, Contopoulos-Ioannidis DG, Biggar RJ: Predictors and impact of losses to follow-up in an HIV-1 perinatal transmission cohort in Malawi. International Journal of Epidemiology 1999, 28:769–775.
Rosen S, Fox MP, Gill CJ: Patient Retention in Antiretroviral Therapy Programs in Sub-Saharan Africa: A Systematic Review. PLoS Medicine 2007, 4:e298.
Lanoy E, Mary-Krause M, Tattevin P, Dray-Spira R, Duvivier C, Fischer P, Obadia Y, Lert F, Costagliola D, Clinical Epidemiology Group of French Hospital Database on HIVI: Predictors identified for losses to follow-up among HIV-seropositive patients. Journal of Clinical Epidemiology 2006, 59:829–835.
Coleman S, Boehmer U, Kanaya F, Grasso C, Tan J, Bradford J: Retention challenges for a community-based HIV primary care clinic and implications for intervention. AIDS Patient Care STDS 2007, 21:691–701.
Lebouche B, Yazdanpanah Y, Gerard Y, Sissoko D, Ajana F, Alcaraz I, Boitte P, Cadore B, Mouton Y: Incidence rate and risk factors for loss to follow-up in a French clinical cohort of HIV-infected patients from January 1985 to January 1998. HIV Medicine 2006, 7:140–145.
Mocroft A, Kirk O, Aldins P, Chies A, Blaxhult A, Chentsova N, Vetter N, Dabis F, Gatell J, Lundgren LD, group ftEs: Loss to follow-up in an international, multicentre observational study. HIV Medicine 2008, 9:261–269.
Cohen CJ, Iwane MK, Palensky JB, Levin DL, Meagher KJ, Frost KR, Mayer KH: A national HIV community cohort: design, baseline, and follow-up of the AmFAR Observational Database. American Foundation for AIDS Research Community-Based Clinical Trials Network. Journal of Clinical Epidemiology 1998, 51:779–793.
Arici C, Ripamonti D, Maggiolo F, Rizzi M, Finazzi MG, Pezzotti P, Suter F: Factors associated with the failure of HIV-positive persons to return for scheduled medical visits. HIV Clinical Trials 2002, 3:52–57.
Brown DM, Thorne JE, Foster GL, Duncan JL, Brune LM, Munana A, Meinert CL, Jabs DA: Factors affecting attrition in a longitudinal study of patients with AIDS. AIDS Care 2006, 18:821–829.
Hessol NA, Schneider M, Greenblatt RM, Bacon M, Barranday Y, Holman S, Robison E, Williams C, Cohen M, Weber K: Retention of Women Enrolled in a Prospective Study of Human Immunodeficiency Virus Infection: Impact of Race, Unstable Housing, and Use of Human Immunodeficiency Virus Therapy. American Journal of Epidemiology 2001, 154:563–573.
Dudley J, Jin S, Hoover D, Metz S, Thackeray R, Chmiel J: The Multicenter AIDS Cohort Study: Retention after 9 1/2 Years. American Journal of Epidemiology 1995, 142:323–330.
South East London Health Protection Unit: The epidemiology of HIV in South East London 1995–2005. London; 2007.
Mortimer JY, Salathiel JA: 'Soundex' codes of surnames provide confidentiality and accuracy in a national HIV database. Communicable Disease Report CDR Review 1995, 5:R183–186.
Bassett IV, Regan S, Chetty S, Giddy J, Uhler LM, Holst H, Ross D, Katz JN, Walensky RP, Freedberg KA, Losina E: Who starts antiretroviral therapy in Durban, South Africa?...not everyone who should. AIDS 2010,24(Suppl 1):S37-S44.
Braitstein P, Boulle A, Nash D, Brinkhof MW, Dabis F, Laurent C, Schechter M, Tuboi SH, Sprinz E, Miotti P, Hosseinpour M, May M, Egger M, Bangsberg DR, Low L, The Antiretrovial Therapy In Lower Income Countries (ART-LINC) Study Group: Gender and the use of antiretroviral treatment in resource-constrained settings: findings from a multicenter collaboration. Journal of Women's Health 2008, 17:47–55.
Muula AS, Ngulube TJ, Siziya S, Makupe CM, Umar E, Prozesky HW, Wiysonge CS, Mataya RH: Gender distribution of adult patients on highly active antiretroviral therapy (HAART) in Southern Africa: a systematic review. BMC Public Health 2007, 7:63.